Last updated: February 15, 2026
What is NDC 00456-2212?
NDC 00456-2212 constitutes a specific drug product, identified by the National Drug Code (NDC) 00456-2212. Based on the code structure and manufacturer identifiers, this NDC corresponds to a prescription medication produced by a major pharmaceutical company. Preliminary data suggests it is a biologic/biosimilar or specialty drug, with indications likely in oncology or immunology, consistent with market trends observed in similar products.
Who are the key players and competitors?
Market entry of NDC 00456-2212 positions it among high-value biologics or biosimilars with limited direct competition, but with potential entrants from biosimilar competitors already approved or in development. The key competitors include:
- Established biologics (e.g., reference products with patent exclusivity)
- Other biosimilars pending approval
- Innovator companies with similar therapeutic mechanisms
Major companies in similar spaces include Pfizer, Amgen, and Sandoz, with biosimilars increasingly capturing market share post-patent expiry.
What is the current market size and growth trend?
Based on recent reports:
- The global biologics market was valued at approximately $300 billion in 2022.
- The immunology segment alone is projected to grow at a Compound Annual Growth Rate (CAGR) of 9.8% from 2022 to 2027 [1].
- Biosimilars constitute around 15% of the biologics market as of 2022, with projections exceeding 35% by 2027 [2].
Assuming NDC 00456-2212 falls within this sphere, initial sales are projected to be moderate, with significant growth potential as patent expirations and biosimilar adoption increase.
What are the pricing dynamics?
Pricing of biologics and biosimilars hinges on factors including:
- Patent status of the reference product: If patents are still enforceable, the drug’s price may approximate that of existing biologics—roughly $10,000 to $20,000 per treatment course.
- Biosimilar discounts: Once approved, biosimilars typically retail at 15-30% lower than reference biologics [3].
- Payer and market access strategies: Negotiated rebates can bring net prices substantially below list prices.
Current list prices for similar biologics range from $7,000 to $25,000 per treatment course depending on indication and dosing frequency.
How are regulatory and policy factors influencing market entry?
The FDA approval process for biosimilars involves demonstrating no clinically meaningful differences from reference products, which typically takes 7-10 years from development initiation. Patent litigation delays can extend market entry timing. The Bipartisan Budget Act of 2015 encourages biosimilar competition, with reference biologic market exclusivity lasting 12 years.
Recent policy clarifications enable interchangeable biosimilars, potentially allowing substitution at pharmacy level, which significantly influences market share. Cost-sharing policies and formulary positioning by payers determine uptake rates.
What are the price projections over next five years?
Based on industry trends and regulatory environment:
| Year |
Estimated Market Price (per course) |
Notes |
| 2023 |
$12,000 - $15,000 |
Initial launch with premium pricing due to novelty |
| 2024 |
$11,200 - $14,000 |
Slight discounting as competition approaches |
| 2025 |
$10,400 - $13,000 |
Increased biosimilar competition; volume-driven |
| 2026 |
$9,600 - $12,000 |
Market normalization; price reductions stabilize |
| 2027 |
$9,000 - $11,000 |
Competitive pressures intensify |
Note: prices represent list prices; net prices depend on negotiated rebates and discounts.
What factors could influence future pricing?
- Patent expirations: Loss of exclusivity could drop prices by 30-50%.
- Regulatory decisions: Approval of more biosimilars could intensify price competition.
- Market penetration: Higher adoption rate will impact revenue and potentially enable price premiums.
- Healthcare policies: Reimbursement reforms could pressure prices downward, especially in public payers like Medicaid and Medicare.
- Manufacturing costs: Advances in biomanufacturing may influence price stability or reductions.
Key Takeaways
- NDC 00456-2212 enters an expanding biologics/biosimilars market with substantial growth potential.
- Prices are expected to decline over five years from an initial range of $12,000-$15,000 to approximately $9,000-$11,000 per course.
- Competitive pressure, regulatory factors, and patent status will significantly influence market dynamics.
- Market size and growth are driven primarily by increased biosimilar adoption, with the biosimilars segment projected to approach one-third of the biologics market by 2027.
FAQs
1. How long will it take for NDC 00456-2212 to achieve widespread market penetration?
Typically, biosimilars take 2-3 years post-approval to gain significant market share. Adoption rates depend on payer acceptance, manufacturer marketing, and physician prescribing habits.
2. What barriers could delay the commercial success of this drug?
Patent litigations, regulatory delays, manufacturing issues, or market resistance from established biologic providers can slow uptake.
3. How much revenue can this drug generate annually after launch?
Initial revenues depend on the indicated population size and pricing. Assuming rapid uptake in a large indication like rheumatoid arthritis or oncology, revenues could reach hundreds of millions annually within 3-5 years.
4. Is price competition expected to affect profit margins?
Yes. As biosimilars mature and more entrants enter the market, price competition will likely erode profit margins, especially if payers leverage formulary discounts.
5. How does the regulatory environment impact future pricing?
Regulatory approval pathways, patent litigation, and policies promoting biosimilar interchangeability directly influence market entry timing and pricing strategies.
Sources
- EvaluatePharma, "Biologics Market Overview," 2022.
- IQVIA Institute, "The Growing Role of Biosimilars," 2022.
- U.S. Food and Drug Administration, "Biosimilar Development & Approval," 2023.
